10-Q: Grace Therapeutics Submits GTx-104 NDA to FDA

Grace Therapeutics, Inc. reported submitting its New Drug Application for lead candidate GTx-104 to the FDA, following positive Phase 3 trial results for aneurysmal subarachnoid hemorrhage.

Summary

• Grace Therapeutics, Inc. (formerly Acasti Pharma Inc.) filed its 10-Q for the quarter ended June 30, 2025.
• The company submitted a New Drug Application (NDA) to the FDA for GTx-104 on June 25, 2025, for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).
• The Phase 3 STRIVE-ON trial for GTx-104 met its primary endpoint, showing a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• Patients receiving GTx-104 also showed a 29% relative increase in favorable outcomes at 90 days follow-up on the modified Rankin scale, and fewer ICU readmissions, ICU days, and ventilator days.
• Net loss for the quarter increased to $3,362 thousand from $2,617 thousand in the prior year, primarily due to a negative change in fair value of derivative warrant liabilities and a decrease in income tax benefit.
• Operating expenses decreased significantly, with research and development expenses falling by $1,753 thousand to $955 thousand, mainly due to the completion of the GTx-104 Phase 3 trial.
• General and administrative expenses also decreased by $120 thousand to $2,135 thousand.
• Net cash used in operating activities decreased to $1,801 thousand from $3,596 thousand in the prior year.
• Cash and cash equivalents stood at $20,005 thousand as of June 30, 2025.
• The company believes its current cash will sustain operations for at least 12 months from the filing date.
• Development of GTx-102 and GTx-101 has been de-prioritized, contingent on securing additional funding or strategic partnerships.
• The company completed a private placement in February 2025, raising net proceeds of $13,705 thousand.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the significant milestone of NDA submission for the lead drug candidate GTx-104, supported by strong Phase 3 clinical data. This represents a major step towards potential commercialization. While the net loss increased, it was largely due to non-operating factors, and the operational cash burn actually decreased. The company has a clear strategic focus and sufficient cash for the next 12 months. However, the reliance on future capital raises for long-term operations and the de-prioritization of other pipeline assets introduce some caution.

Positives

• Submitted New Drug Application (NDA) for lead candidate GTx-104 to the FDA, a major regulatory milestone.
• GTx-104's Phase 3 STRIVE-ON trial met its primary endpoint, demonstrating a 19% reduction in clinically significant hypotension compared to oral nimodipine.
• Clinical data for GTx-104 showed a 29% relative increase in favorable outcomes at 90 days and reduced ICU days, readmissions, and ventilator days, indicating potential clinical benefit.
• Pharmacoeconomic measures favored GTx-104, suggesting potential cost-effectiveness for hospitals.
• GTx-104 offers 100% bioavailability compared to approximately 7% for oral nimodipine, leading to significantly less variability.
• Operating expenses decreased significantly, with research and development expenses down by $1,753 thousand due to trial completion.
• Net cash used in operating activities decreased by $1,795 thousand, indicating improved operational cash burn.
• The company has sufficient cash and cash equivalents ($20,005 thousand) to sustain planned operations for at least 12 months.

Negatives

• Net loss increased to $3,362 thousand for the quarter, up from $2,617 thousand in the prior year, primarily due to non-operating factors.
• A negative change in the fair value of derivative warrant liabilities ($487 thousand vs. $1,395 thousand gain in prior year) contributed significantly to the increased net loss.
• The company recorded no income tax benefit for the quarter, compared to a $724 thousand benefit in the prior year, due to a partial valuation allowance against deferred tax assets.
• Development of GTx-102 and GTx-101 has been de-prioritized, with future progress dependent on external funding or partnerships.
• The company does not expect to generate revenue from product sales until regulatory approval for GTx-104, which is subject to significant uncertainty.
• The company will require additional capital beyond the next 12 months to fund daily operating needs and further development.

Risks

• Heavy dependence on the successful development and commercialization of the lead drug candidate, GTx-104.
• Clinical development is a lengthy, expensive process with uncertain outcomes, and earlier trial results may not predict future success.
• Subject to uncertainty regarding healthcare reform measures and reimbursement policies, which could hinder commercial success if unfavorable.
• Inability to establish sales and marketing capabilities or secure third-party agreements could prevent revenue generation.
• Difficulty differentiating drug products from branded reference drugs or existing generic therapies, or approval of competing products, could adversely affect commercialization.
• Success depends on the ability to protect intellectual property for drug candidates.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Lack of internal manufacturing capabilities and reliance on third-party manufacturers (CMOs) and contract research organizations (CROs) poses supply and quality risks.
• Contract manufacturers may face difficulties with production yields, regulatory compliance, quality control, and personnel shortages, potentially delaying or denying drug candidate approval.
• The design, development, manufacture, supply, and distribution of drug candidates are highly regulated and technically complex.
• Need for additional financing; inability to raise capital on acceptable terms could negatively impact financial condition and business strategy.
• Negative results from studies or trials, or depressed stock prices, could impair the ability to raise additional financing.
• Raising additional equity capital is subject to market conditions beyond the company's control.

Future Outlook

The company is focused on the regulatory review process for GTx-104, pre-commercial planning, commercial team buildout, and product launch if approved. It expects to incur significant expenses and continued operating losses for the foreseeable future. Additional capital will be required to fund daily operating needs beyond the next 12 months, expected to be sourced from public or private equity/debt financing or non-dilutive sources like collaborations. The company plans to maximize the value of de-prioritized drug candidates GTx-102 and GTx-101 through potential development, licensing, or sale, contingent on additional funding or strategic partnerships.

Management Comments

• "We believe our existing cash and cash equivalents will be sufficient to sustain planned operations through at least 12 months from the issuance date of these unaudited condensed consolidated financial statements."
• "The Company will require additional capital to fund its daily operating needs."
• "The Company does not expect to generate revenue from product sales unless and until it obtains regulatory approval for GTx-104, which is subject to significant uncertainty."
• "Until such time that the Company can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financing or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties."
• "Our inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy."
• "We plan to raise additional capital in order to maintain adequate liquidity."
• "Negative results from studies or trials, if any, the timing and ability to receive FDA approval for marketing our drug candidates or depressed prices of the Company's stock could impact the Company's ability to raise additional financing."
• "Raising additional equity capital is subject to market conditions that are not within the Company's control."

Industry Context

Grace Therapeutics operates in the biopharmaceutical industry, specifically targeting rare and orphan diseases, which often benefit from Orphan Drug Designation (ODD) and exclusivity (ODE) incentives like tax credits and market protection. The company's strategy of applying novel formulations to existing pharmaceutical compounds (505(b)(2) pathway) is a common approach to potentially accelerate regulatory approval by leveraging established safety and efficacy profiles. Its focus on improving the delivery of nimodipine for aSAH addresses a known unmet need with an existing standard of care, while its de-prioritized candidates target diseases with no currently approved therapies (A-T) or seek to improve upon existing treatments (PHN). The industry is characterized by high R&D costs, lengthy development timelines, and significant regulatory hurdles, making successful NDA submissions and positive clinical data critical milestones.

Comparison to Industry Standards

• GTx-104's development leverages the Section 505(b)(2) regulatory pathway, a common industry strategy for reformulated drugs, potentially offering a shorter path to approval compared to novel chemical entities.
• The company's pursuit of Orphan Drug Designation (ODD) for its candidates aligns with industry practices to gain market exclusivity (7 years for ODE) and financial incentives (25% tax credits on U.S. clinical development costs, NDA fee waiver of approximately $4.3 million for GTx-104).
• GTx-104 aims to improve upon the existing oral nimodipine (generic and branded NYMALIZE by Azurity Pharmaceuticals) for aSAH, addressing issues like poor water solubility, low bioavailability, and administration difficulties, a common value-add strategy in drug development.
• GTx-102 targets Ataxia-Telangiectasia (A-T), a rare neurodegenerative disorder with no FDA-approved therapies, positioning it to potentially be a first-in-class treatment, similar to other companies pursuing unmet medical needs in orphan diseases.
• GTx-101 aims to provide a superior topical treatment for Postherpetic Neuralgia (PHN) compared to current standards like oral gabapentin and lidocaine patches, addressing issues like insufficient pain relief, application difficulties, and skin sensitivity reported with existing options.

Corporate Governance

Legal Proceedings

• The company is subject to various legal proceedings and disputes in the ordinary course of business.
• Management assesses liabilities and contingencies for probable and estimable losses, recording liabilities as needed.
• No reserves or liabilities have been accrued for legal contingencies as of June 30, 2025.
• Management believes appropriate legal reserves have been established, but ultimate resolution could be material if unfavorable.
• The company is not currently a party to any legal proceedings deemed likely to have a material adverse effect on its business.

Related Party Transactions

• In the February 2025 Private Placement, Common Stock, 2025 Pre-Funded Warrants, and 2025 Common Warrants were issued to related parties, including Shore Pharma LLC (held in trust for immediate family members of the Board Chair), ADAR1 Partners, LP, AIGH Investment Partners, LP, and SS Pharma LLC (beneficial owners of more than 5% of Common Stock prior to the placement), resulting in proceeds of $5,694 thousand.
• In the September 2023 Private Placement, Common Shares, 2023 Pre-Funded Warrants, and 2023 Common Warrants were issued to related parties, including Shore Pharma LLC (controlled by the Board Chair at the time) and SS Pharma LLC (beneficial owner of 5.5% of Common Shares prior to the placement), resulting in proceeds of $2,500 thousand.
• As of June 30, 2025, the balance of derivative warrant liabilities from related parties was $1,357 thousand (compared to $952 thousand as of March 31, 2025).

Stakeholder Impact

• **Shareholders**: The NDA submission for GTx-104 and positive Phase 3 results could significantly increase shareholder value if approved. However, continued operating losses and the need for future capital raises pose dilution risks. The increased net loss, while primarily non-operating, impacts reported earnings.
• **Patients (aSAH)**: GTx-104, if approved, offers a potentially improved treatment option for aneurysmal subarachnoid hemorrhage patients, addressing limitations of current oral nimodipine administration.
• **Patients (A-T, PHN)**: The de-prioritization of GTx-102 and GTx-101 means that patients with Ataxia-Telangiectasia and Postherpetic Neuralgia will have to wait longer for potential new therapies from Grace Therapeutics, unless partnerships are secured.
• **Employees**: The strategic realignment in May 2023 resulted in a reduced workforce, indicating a more focused but smaller organization. Stock-based compensation continues to be a component of employee remuneration.
• **Creditors/Investors**: The company's liquidity position is sufficient for the next 12 months, but the explicit need for future capital raises highlights ongoing financial risk for potential creditors and investors.
• **Third-Party Contractors (CROs/CMOs)**: The company continues to rely heavily on CROs for clinical trials and CMOs for manufacturing, indicating ongoing business for these partners, but also a dependency for Grace Therapeutics.

Next Steps

• FDA review and potential acceptance of the NDA for GTx-104.
• Pre-commercial planning and commercial team buildout for GTx-104.
• Product launch for GTx-104 if approved by the FDA.
• Collaborate with scientific advisory board and FDA (via Type C meeting) on the design of a potential pivotal efficacy and safety trial for GTx-102.
• Determine next steps for GTx-102 after FDA feedback and collaboration.
• Seek additional funding or strategic partnerships for the further development, licensing, or sale of GTx-102 and GTx-101.
• Initiate a multiple ascending dose trial for GTx-101, pending additional funding or strategic partnership.
• Conduct non-clinical studies and clinical trials for GTx-101 before initiating a Phase 2 program in PHN patients.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and disclosures.

Key Dates

Recommendation

Grace Therapeutics has achieved a significant milestone with the NDA submission for GTx-104, backed by positive Phase 3 data, which is a strong positive for a pre-revenue biotech. The reduction in operating cash burn is also favorable. However, the company remains pre-revenue, reported an increased net loss (though largely due to non-operating items), and explicitly states a need for future capital raises beyond the next 12 months. This reliance on future financing and the de-prioritization of other pipeline assets introduce considerable risk. A 'Hold' recommendation is appropriate for a seasoned investor, acknowledging the substantial progress and potential upside of GTx-104, while also recognizing the inherent risks and funding challenges typical of a clinical-stage biopharmaceutical company.

Keywords

Grace Therapeutics, GTx-104, NDA submission, FDA approval, aneurysmal subarachnoid hemorrhage, aSAH, nimodipine, Phase 3 trial, STRIVE-ON, biopharmaceutical, rare disease, orphan drug, drug development, clinical trials, biotech, pharmaceuticals, SEC filing, 10-Q